RESUMO
Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rßγ > IL-2 Rßγ and abolished binding to IL-2 Rα. Here, we investigated the immunostimulatory properties of FAP-IL2v and its combination with programmed cell death protein 1 (PD-1) checkpoint inhibition, CD40 agonism, T cell bispecific and antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. The binding and immunostimulatory properties of FAP-IL2v were investigated in vitro and compared with FAP-IL2wt. Tumor targeting was investigated in tumor-bearing mice and in a rhesus monkey. The ability of FAP-IL2v to potentiate the efficacy of different immunotherapies was investigated in different xenograft and syngeneic murine tumor models. FAP-IL2v bound IL-2 Rßγ and FAP with high affinity in vitro, inducing dose-dependent proliferation of natural killer (NK) cells and CD4+/CD8+ T cells while being significantly less potent than FAP-IL2wt in activating immunosuppressive regulatory T cells (Tregs). T cells activated by FAP-IL2v were less sensitive to Fas-mediated apoptosis than those activated by FAP-IL2wt. Imaging studies demonstrated improved tumor targeting of FAP-IL2v compared to FAP-IL2wt. Furthermore, FAP-IL2v significantly enhanced the in vitro and in vivo activity of therapeutic antibodies that mediate antibody-dependent or T cell-dependent cellular cytotoxicity (TDCC) and of programmed death-ligand 1 (PD-L1) checkpoint inhibition. The triple combination of FAP-IL2v with an anti-PD-L1 antibody and an agonistic CD40 antibody was most efficacious. These data indicate that FAP-IL2v is a potent immunocytokine that potentiates the efficacy of different T- and NK-cell-based cancer immunotherapies.
Assuntos
Antineoplásicos/farmacologia , Proteínas de Membrana/antagonistas & inibidores , Neoplasias Experimentais/patologia , Proteínas Recombinantes de Fusão/farmacologia , Animais , Anticorpos Monoclonais/farmacologia , Citocinas/farmacologia , Endopeptidases , Humanos , Imunoterapia/métodos , Ativação Linfocitária/efeitos dos fármacos , Macaca mulatta , Camundongos , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
Transduction of therapeutic transgenes using multiply attenuated viral vectors is considered an essential technology for gene therapy scenarios. While first-generation viral transduction systems were engineered for constitutive expression of a single therapeutic transgene, most advanced viral gene-transfer technologies enable regulated expression of several transgenes. Efficient transfer of numerous transgenes enables co-expression of therapeutic transgenes along with marker or selection determinants, production of multi-subunit protein complexes, or combinatorial expression of a particular set of genes to treat multigenic disorders. Likewise, adjustable transcription control is fundamental to adapt therapeutic protein production to the changing daily dosing regimes of a patient, to titrate expression of protein pharmaceuticals into the therapeutic window, and to reverse dosing upon completion of the therapy. Also, conditional transcription dosing has been successfully used for production of difficult-to-express protein therapeutics in biopharmaceutical manufacturing and for sophisticated gene-function analysis in basic research programs. By way of example, we provide detailed design (auto-regulated and binary dual-regulated expression configurations), production (generation, purification, and quality control of transgenic adenovirus particles), and handling (transduction) protocols for adenovirus vectors that enable transduction of mammalian cells for regulated expression of several transgenes.
Assuntos
Adenoviridae/genética , Fosfatase Alcalina/metabolismo , Regulação da Expressão Gênica , Vetores Genéticos/fisiologia , Transdução Genética , Transgenes/fisiologia , Fosfatase Alcalina/genética , Animais , Antibacterianos/farmacologia , Aorta/citologia , Aorta/efeitos dos fármacos , Aorta/metabolismo , Células CHO , Células Cultivadas , Cricetinae , Cricetulus , Feminino , Fibroblastos/citologia , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Humanos , Rim/metabolismo , Placenta/enzimologia , Estreptograminas/farmacologia , Tetraciclina/farmacologiaRESUMO
PURPOSE: Imgatuzumab (GA201) is a novel anti-EGFR mAb that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Future treatment schedules for imgatuzumab will likely involve the use of potentially immunosuppressive drugs, such as premedication therapies, to mitigate infusion reactions characteristic of mAb therapy and chemotherapy combination partners. Because of the strong immunologic component of mode of action of imgatuzumab, it is important to understand whether these drugs influence imgatuzumab-mediated ADCC and impact efficacy. EXPERIMENTAL DESIGN: We performed a series of ADCC assays using human peripheral blood mononuclear cells that were first preincubated in physiologically relevant concentrations of commonly used premedication drugs and cancer chemotherapies. The ability of common chemotherapy agents to enhance the efficacy of imgatuzumab in vivo was then examined using orthotopic xenograft models of human cancer. RESULTS: A majority of premedication and chemotherapy drugs investigated had no significant effect on the ADCC activity of imgatuzumab in vitro Furthermore, enhanced in vivo efficacy was seen with imgatuzumab combination regimens compared with single-agent imgatuzumab, single-agent chemotherapy, or cetuximab combinations. CONCLUSIONS: These data indicate that medications currently coadministered with anti-EGFR therapies are unlikely to diminish the ADCC capabilities of imgatuzumab. Further studies using syngeneic models with functional adaptive T-cell responses are now required to fully understand how chemotherapy agents will influence a long-term response to imgatuzumab therapy. Thus, this study and future ones can provide a framework for designing imgatuzumab combination regimens with enhanced efficacy for investigation in phase II trials. Clin Cancer Res; 22(10); 2453-61. ©2015 AACR.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Citotoxicidade Celular Dependente de Anticorpos/efeitos dos fármacos , Antineoplásicos/uso terapêutico , Células A549 , Linhagem Celular Tumoral , Cetuximab/uso terapêutico , Terapia Combinada/métodos , Receptores ErbB/antagonistas & inibidores , Células HT29 , Humanos , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/metabolismoRESUMO
The effect of intrastriatal administration of LY306740, a specific NK-1 receptor antagonist, on the behavior and changes in gene expression elicited by the psychomotor stimulant, amphetamine, was studied. Acute administration of amphetamine (2.5 mg/kg, i.p.) caused an increase in behavioral activity and preproenkephalin, preprodynorphin and substance P mRNA expression in the striatum. When amphetamine-treated rats were pretreated with LY306740 (35 and 20 nmoles per side, intrastriatally), there was a significant decrease in amphetamine-induced behavioral activity. Quantitative in situ hybridization histochemistry revealed that both concentrations of LY306740 significantly decreased amphetamine-induced mRNA expression of all three neuropeptides. These data indicate that striatal NK-1 receptors modulate amphetamine-induced behavior and mRNA expression of neuropeptides in the rat striatum.
Assuntos
Acetamidas/farmacologia , Anfetamina/antagonistas & inibidores , Comportamento Animal/efeitos dos fármacos , Estimulantes do Sistema Nervoso Central/antagonistas & inibidores , Corpo Estriado/metabolismo , Antagonistas dos Receptores de Neurocinina-1 , Neuropeptídeos/biossíntese , RNA Mensageiro/biossíntese , Anfetamina/farmacologia , Animais , Área Sob a Curva , Estimulantes do Sistema Nervoso Central/farmacologia , Corpo Estriado/efeitos dos fármacos , Dinorfinas/biossíntese , Dinorfinas/genética , Regulação da Expressão Gênica/efeitos dos fármacos , Hibridização In Situ , Masculino , Microinjeções , Atividade Motora/efeitos dos fármacos , Precursores de Proteínas/biossíntese , Precursores de Proteínas/genética , Ratos , Ratos Sprague-Dawley , Convulsões/induzido quimicamente , Sono/efeitos dos fármacos , Substância P/biossíntese , Substância P/genéticaRESUMO
BACKGROUND: Adenoviral particles can efficiently transduce a broad spectrum of cell types, so they are widely used in basic research and clinical trials. METHODS: We have developed a novel adenoviral vector platform for delivery of constitutive or streptogramin-inducible expression of up to three therapeutic transgenes into a variety of murine and human cell lines, primary cells and microtissues. RESULTS: Coordinated expression of three independent transgenes in a compact genetic format was achieved by two different expression configurations: (i) The multicistronic expression format consisting of a single constitutive (simian virus 40 promoter, P(SV40); murine or human cytomegalovirus immediate-early promoter, P(mCMV), P(hCMV)) or regulated (streptogramin-inducible) promoters (P(PIR)ON2) driving the expression of a single multicistronic transcript of which the first cistron is translated in a cap-dependent manner and the two subsequent ones by internal ribosome entry site (IRES)-mediated translation initiation. (ii) The triple-transcript expression configuration, in which a combination of well-established (P(SV40), P(hCMV), P(mCMV)) and novel synthetic constitutive promoters (P(GTX)) control transcription of three expression units. The constitutive multigene expression design enabled coordinated high-level expression of the Bacillus stearothermophilus-derived secreted alpha-amylase (SAMY), the human vascular endothelial growth factor 121 (VEGF(121)) and the human placental secreted alkaline phosphatase (SEAP) in monolayer populations and microtissues of Chinese hamster ovary cells (CHO-K1), human fibrosarcoma cells (HT-1080), primary neonatal rat cardiomyocytes (NRCs) and primary human aortic fibroblasts (HAFs). Streptogramin-inducible tricistronic SAMY-VEGF(121)-SEAP expression provided excellent regulation performance-high-level induction in the presence of the streptogramin antibiotic pristinamycin I (PI), near-undetectable basal expression in the absence of PI, optimal adjustability and perfect reversibility-in all cell types, in particular in NRCs and NRC-derived myocardial microtissues. CONCLUSIONS: Triple-transcript and tricistronic expression configurations conserve the DNA packaging capacity of the size-constrained viral transduction systems and enable coordinated and regulated expression of up to three therapeutic transgenes for concerted clinical interventions in future gene therapy scenarios.
Assuntos
Adenoviridae/genética , Vetores Genéticos/síntese química , Transdução Genética/métodos , Transgenes , Animais , Células CHO , Células Cultivadas , Cricetinae , Regulação da Expressão Gênica/efeitos dos fármacos , Genes , Engenharia Genética/métodos , Humanos , Ratos , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Regulon , Estreptograminas/farmacologia , Transgenes/efeitos dos fármacosRESUMO
BACKGROUND: Stringent multitransgene control is a prerequisite for future gene-therapy and tissue-engineering scenarios and requires constant improvements in design to achieve optimal conditional transcription profiles. METHODS: We have pioneered a variety of recombinant adenoviruses which (i) enable streptogramin-responsive transgene transduction in a compact autoregulated one-virus format, (ii) manage independent streptogramin- and tetracycline-responsive control of two different transgenes from a single divergent expression unit, and (iii) control sense and antisense expression of the human cyclin-dependent kinase inhibitor p27(Kip1) to engineer conditional positive (enforced S-phase entry, p27(Kip1)-antisense expression) or negative (G1-phase-specific growth arrest, p27(Kip1)-sense expression) growth control in mammalian cell lines and human primary cells. RESULTS: The transgene control performance of all adenoviral expression configurations has been rigorously optimized for tight, balanced and maximum expression levels and was validated for intracellular as well as for secreted product in a variety of biotechnologically relevant cell lines (Chinese hamster ovary cells [CHO-K1], baby hamster kidney cells [BHK-21]) as well as in human cell lines (human fibrosarcoma cells [HT-1080]) and primary cells (human aortic fibroblasts [HAFs]). CONCLUSIONS: We believe that multiregulated multigene-controlled adenoviruses are important assets for successful therapeutic reprogramming of mammalian cells in clinically relevant scenarios.
Assuntos
Inibidor de Quinase Dependente de Ciclina p27/metabolismo , Regulação da Expressão Gênica , Vetores Genéticos/genética , Transfecção/métodos , Adenoviridae , Animais , Células CHO , Linhagem Celular , Cricetinae , Cricetulus , Genes Reporter/genética , Humanos , Estreptograminas , Tetraciclina , Transgenes/genéticaRESUMO
Despite decisive progress in understanding the molecular biology of cancer development, cytotoxic anticancer drugs continue to be the cornerstone of modern antitumor therapies. The developmental therapeutics program, initiated by the US National Institutes of Health's National Cancer Institute in the early 1990s, pioneered massive-scale screening for agents able to phenotypically interfere with the growth and viability of neoplastic cell lines derived from a representative panel of human carcinogenic tissues. Capitalizing on advanced knowledge of molecular processes particular for neoplastic cell characteristics, target-specific screening scenarios became since increasingly popular. With drug targets defined, natural and synthetic (combinatorial) compound/peptide/nucleic acid libraries available and the high-throughput screening technology of the systems' biology era in place, the quo vadis of anticancer drug discovery seems to be well determined. We review recent advances in cytotoxic anticancer drug assay design with emphasis on a novel mammalian cell-based anticancer drug finder technology for the discovery of cytotoxic drugs with fewer side-effects on non-dividing cells.
Assuntos
Antineoplásicos/farmacologia , Ensaios de Seleção de Medicamentos Antitumorais/métodos , Animais , Cricetinae , Cricetulus , Humanos , Biologia Molecular , Células Tumorais CultivadasRESUMO
Changes in gene/protein expression markedly outlast the transient changes in behavior evoked by a single dose of a psychostimulant. These changes in gene expression are thought to underlie and/or trigger enduring changes in neuroplasticity that lead to drug addiction. We used cDNA arrays to gain a more complete picture of changes in striatal gene expression 1 and 3 h after an acute injection of amphetamine. Consistent, reliable gene expression changes were detected when criteria of at least a 1.5-fold difference and three replicate hybridizations using independent samples were performed. Using these criteria, the mRNA for three immediate early genes (IEGs), coding for activity-regulated cytoskeletal-associated protein (Arc), nerve growth factor-induced protein A (NGFI-A; early growth response protein 1) and nerve growth factor-induced protein B (NGFI-B), were upregulated 1 and 3 h after amphetamine as previously described. Novel genes, RL/IF-1 (coding for I kappa B alpha chain) and serum/glucocorticoid-regulated serine/threonine protein kinase (SGK) also were increased throughout the striatum, at 1 but not 3 h. Conversely, amphetamine increased the mRNA coding for the secretogranin II precursor (chromogranin C) only at the 3 h time point when a specific decrease in regulator of G-protein signaling 4 (RGS4) mRNA was also observed. Gene changes and unique patterns of expression were verified by in situ hybridization, providing valuable information about changes in gene expression in response to acute amphetamine.
Assuntos
Anfetamina/farmacologia , Corpo Estriado/fisiologia , DNA Complementar/genética , Perfilação da Expressão Gênica , Proteínas do Tecido Nervoso/genética , RNA Mensageiro/genética , Animais , Corpo Estriado/citologia , Corpo Estriado/efeitos dos fármacos , Genes Precoces , Histocitoquímica , Proteínas Imediatamente Precoces/genética , Hibridização In Situ , Cinética , Especificidade de Órgãos , RNA Mensageiro/análise , Ratos , Fatores de TempoRESUMO
A key asset of cytotoxic drugs in cancer therapeutics is their ability to discriminate between proliferating and mitotically inert cells and eliminate preferentially neoplastic ones. We have designed a high throughput-compatible mammalian cell-based assay for the discovery of cytotoxic drugs, which selectively kill proliferation-competent target cells. This cytotoxic drug discovery assay is based on a transgenic CHO-K1-derived cell line engineered for a conditional G1-specific growth arrest following tetracycline-responsive overexpression of the human cyclin-dependent kinase inhibitor p27(Kip1). The CHO-derived cell line CHO-p27(Kip1) shows wild type proliferation rates and can be expanded in the presence of tetracycline antibiotics when p27(Kip1) expression is repressed. Upon withdrawal of regulating antibiotics CHO-p27(Kip1) differentiates into a 1:1 mixed population consisting of two different proliferation phenotypes: (i) a G1-arrested cell population induced by heterologous expression of p27(Kip1) which mimics mitotically inactive terminally differentiated cells and (ii) a proliferation-competent cell population which eliminated the p27(Kip1) expression unit and imitates neoplastic cell characteristics. Addition of chemical or metabolic libraries to CHO-p27(Kip1) populations cultivated in tetracycline-free medium followed by scoring for cell viability will reveal cytotoxic drug candidates associated with a high viability ratio of proliferation-competent/arrested populations. We have validated the cell-based cytotoxic drug discovery assay using the clinically licensed cancer drugs mitomycin C, doxorubicin, etoposide and 5-fluorouracil. Comparative proof-of-concept studies showed that these top-prescribed cancer therapeutics preferentially eliminate proliferating cells while showing less interference with the viability of G1-arrested cell populations. These results demonstrate the CHO-p27(Kip1)-based cytotoxic drug finder technology is ready-to-apply for high throughput screenings of chemical as well as metabolic libraries to discover novel cancer therapeutics which show reduced cytotoxicity on terminally differentiated cells.
Assuntos
Antineoplásicos/farmacologia , Bioensaio/métodos , Ensaios de Seleção de Medicamentos Antitumorais/métodos , Animais , Células CHO , Proteínas de Ciclo Celular/biossíntese , Divisão Celular/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Cricetinae , Inibidor de Quinase Dependente de Ciclina p27 , Doxorrubicina/farmacologia , Desenho de Fármacos , Etoposídeo/farmacologia , Imunofluorescência , Fluoruracila/farmacologia , Mitomicina/farmacologia , Transfecção , Proteínas Supressoras de Tumor/biossínteseRESUMO
In the past decade, regenerative medicine has evolved as an interdisciplinary field, integrating expertise from the medical, life- and material-science communities. Recent advances in tissue engineering, gene therapy, gene-function analysis, animal-free drug testing, drug discovery, biopharmaceutical manufacturing and cell-phenotype engineering have capitalized on a core technology portfolio including artificial microtissue design, viral transduction and precise transcription dosing of therapeutic or phenotype-modulating transgenes. We provide a detailed overview on recent progress in these core technologies and comment on their synergistic impact on current and future human therapies.